SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Cutler SJ, Young JL. Third National Cancer Survey: incidence data. Washington, DC: Department of Health, Education, and Welfare; 1975 DHEW Pub. No. (NIH) 75787.
  • 2
    Axtell LM, Myers MH. Contrasts in survival of black and white cancer patients, 1960-73. J Natl Cancer Inst 1978; 60: 1209-15.
  • 3
    Ries LG, Pollack ES, Young JL Jr.. Cancer patient survival: Surveillance, Epidemiology, and End Results, 1973-79. J Natl Cancer Inst 1983; 70: 693-707.
  • 4
    Young JL Jr., Ries LG, Pollack ES. Cancer patient survival among ethnic groups in the United States. J Natl Cancer Inst 1984; 73: 341-52.
  • 5
    Natarajan N, Nemoto T, Mettlin C, Murphy GP. Race-related differences in breast cancer patients. Cancer 1985; 56: 1704-9.
  • 6
    MillerBA, RiesLAG, HankeyBF, KosaryCL, HarrasA, DevesaSS, et al., editors. SEER Cancer Statistics Review 1973-1990. Bethesda, (MD): National Cancer Institute; 1993 NIH Pub. No. 932789.
  • 7
    Valanis B, Wirman J, Hertzberg V. Social and biologic factors in relation to survival among black versus white women with breast cancer. Breast Cancer Res Treat 1987; 9: 135-44.
  • 8
    Crowe JP, Gordon NH, Hubay CA, Pearson OH, Marshall JS, McGuire WL. The interaction of estrogen receptor status and race in predicting prognosis for Stage I breast cancer patients. Surgery 1986; 100: 599-605.
  • 9
    Shwartz AG, Ragheb NE, Swanson GM, Satariano WA. Racial and age differences in multiple primary cancers after breast cancer: a population-based analysis. Breast Cancer Res Treat 1989; 14: 245-54.
  • 10
    Bain RP, Greenberg RS, Whitaker JP. Racial differences in survival of women with breast cancer. J Chron Dis 1986; 39: 631-42.
  • 11
    Ragland KE, Selvin S, Merril DW. Black-white differences in stage-specific cancer survival: analysis of seven selected sites. Am J Epidemiol 1991; 133: 672-82.
  • 12
    Ownby HE, Frederick J, Russo J, Brooks SC, Swanson GM, Heppner GH, et al. Racial differences in breast cancer patients. J Natl Cancer Inst 1985; 75: 55-60.
  • 13
    Shapiro S, Venet W, Strax P, Venet L, Roeser R. Prospects for eliminating racial differences in breast cancer survival rates. Am J Public Health 1982; 72: 1142-5.
  • 14
    Satariano WP, Belle SH, Swanson GM. The severity of breast cancer at diagnosis: a comparison of age and extent of disease in black and white women. Am J Public Health 1986; 76: 779-82.
  • 15
    McWhorter WP, Mayer WJ. Black/white differences in type of initial breast cancer treatment and implications for survival. Am J Public Health 1987; 77: 1515-7.
  • 16
    Hand R, Sener S, Imperato J, Chmiel JS, Sylvester J, Fremgen A. Hospital variables associated with quality of care for breast cancer patients. JAMA 1991; 266: 3429-32.
  • 17
    Polednak AP. Breast cancer in black and white women in New York State. Cancer 1986; 58: 807-15.
  • 18
    Basset MT, Krieger N. Social class and black-white differences in breast cancer survival. Am J Public Health 1986;76:1400-3.19. Vernon SW, Tilley BC, Neale AV, Steinfeldt L. Ethnicity, survival, and delay in seeking treatment for symptoms of breast cancer. Cancer 1985; 55: 1563-71.
  • 19
    Keirn W, Mettler G. Survival of cancer patients by economic status in a free care setting. Cancer 1985; 55: 1552-5.
  • 20
    Gordon NH, Crowe JP, Brumberg DJ, Berger NA. Socioeconomic factors and race in breast cancer recurrence and survival. Am J Epidemiol 1992; 135: 609-18.
  • 21
    Polednak AP. Cancer mortality in a higher-income black population in New York State. Cancer 1990; 66: 1654-60.
  • 22
    Dayal HH, Power RN, Chiu C. Race and socio-economic status in survival from breast cancer. J Chron Dis 1982; 35: 675-83.
  • 23
    Fisher B, Redmond C, Dimitrov NV, Bowman D, Legault-Poisson S, Wickerham DL, et al. A randomized clinical trial evaluating sequential methotrexate and fluorouracil in the treatment of patients with node-negative breast cancer who have estrogen-receptor-negative tumors. N Engl J Med 1989; 320: 473-8.
  • 24
    Fisher B, Costantino J, Redmond C, Poisson R, Bowman D, Couture J, et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med 1989; 320: 479-84.
  • 25
    Kohail HM, Elias EG, El-Nowiem SA, Bashirelahi N, Didolkar MS, Reed WP. A multifactorial analysis of steroid hormone receptors in Stage I and II breast cancer. Ann Surg 1985; 201: 611-7.
  • 26
    Mohla S, Sampson CC, Khan T, Enterline JP, Leffall L Jr., White JE, et al. Estrogen and progesterone receptors in breast cancer in black Americans. Cancer 1982; 50: 552-9.
  • 27
    Stanford JL, Greenberg RS. Breast cancer incidence in young women by estrogen receptor status and race. Am J Public Health 1989; 79: 71-3.
  • 28
    Beverly LN, Flanders WD, Go RC, Soong SJ. A comparison of estrogen and progesterone receptors in black and white breast cancer patients. Am J Public Health 1987; 77: 351-3.
  • 29
    Pierce L, Fowble B, Solin LJ, Schultz DJ, Rosser C, Goodman RL. Conservative surgery and radiation therapy in black women with early stage breast cancer. Cancer 1992; 69: 2831-41.
  • 30
    Fisher ER, Redmond CK, Fisher B. Prognostic factors in NSABP studies of women with node-negative breast cancer. J Natl Cancer Inst Monogr 1992; 11: 151-8.
  • 31
    Fisher B, Dignam J, Mamounas E, Costantino JP, Wickerham DL, Redmond C, et al. Sequential methotrexate and fluorouracil (M[RIGHTWARDS ARROW]F) in the treatment of node-negative breast cancer patients: eight year results from NSABP B-13 and first report of findings from NSABP B-19 comparing M[RIGHTWARDS ARROW]F with conventional cyclophosphamide, methotrexate and fluorouracil (CMF). J Clin Oncol 1996; 14: 1982-92.
  • 32
    Fisher B, Dignam J, Bryant J, DeCillis A, Wickerham DL, Wolmark N, et al. Five versus more than five years of tamoxifen for breast cancer patients with negative lymph nodes and estrogen-receptor positive tumors. J Natl Cancer Inst 1996; 88: 1429-42.
  • 33
    Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-81.
  • 34
    Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966; 50: 163-70.
  • 35
    Rosner B. Fundamentals of biostatistics. 4th edition. Belmont, CA: Duxbury Press, 1995.
  • 36
    Cox DR. Regression models and life tables. J R Stat Soc [B] 1972; 34: 187-220.
  • 37
    Makuch RW. Adjusted survival curve estimation using covariates. J Chron Dis 1982; 35: 437-43.
  • 38
    Prentice RL, Kalbfleish JD, Peterson AV, Flournoy N, Farewell VT, Breslow NE. The analysis of failure times in the presence of competing risks. Biometrics 1978; 34: 541-54.
  • 39
    Chen VW, Correa P, Kurman RJ, Wu XC, Eley WJ, Austin D, et al. Histological characteristics of breast carcinoma in blacks and whites. Cancer Epidemiol Biomarkers Prev 1994; 3: 127-35.
  • 40
    Briele HA Jr., Walker MJ, Wild L, Wood DR, Greager JA, Schneebaum S, et al. Results of treatment of Stage I-III breast cancer in black Americans. The Cook County Hospital experience 1973-1987. Cancer 1990; 65: 1062-71.
  • 41
    Lazovich D, White E, Thomas DB, Moe RE. Under-utilization of breast-conserving surgery with radiation therapy among women with Stage I or II breast cancer. JAMA 1991; 266: 3433-8.